NASH Clinical Trials
Saroglitazar Magnesium for the Treatment of Nonalcoholic Steatohepatitis with Fibrosis
A phase 2b, prospective, multicenter, randomized, double-blind, placebo-controlled study to evaluate efficacy and safety of saroglitazar magnesium in subjects with nonalcoholic steatohepatitis and fibrosis
ClinicalTrials.gov Identifier: NCT05011305
Saroglitazar Magnesium for the Treatment of Nonalcoholic Steatohepatitis with Fibrosis
A phase 2b, prospective, multicenter, randomized, double-blind, placebo-controlled study to evaluate efficacy and safety of saroglitazar magnesium in subjects with nonalcoholic steatohepatitis and fibrosis
ClinicalTrials.gov Identifier: NCT05011305
Saroglitazar Magnesium 4 mg for NASH in People Living With HIV in the US (SARONAPLUS)
A randomized, double-blind, placebo-controlled, multicenter trial of saroglitazar magnesium for the treatment of nonalcoholic steatohepatitis (NASH) in people living with human immunodeficiency virus (HIV) in the US
ClinicalTrials.gov Identifier: NCT05211284
Saroglitazar Magnesium 4 mg in the Treatment of NAFLD in Women With PCOS (EVIDENCES VII)
A multicenter, phase 2A, randomized, double-blind, placebo-controlled study designed to evaluate the efficacy and safety of Saroglitazar Magnesium in women with well characterized PCOS
ClinicalTrials.gov Identifier: NCT03617263